Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Chinese Patent Office
Accenture
Cipla
UBS
Daiichi Sankyo
QuintilesIMS
US Army
Colorcon

Generated: June 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,500,867

« Back to Dashboard

Summary for Patent: 6,500,867
Title: Pharmaceutical composition comprising entacapone, levodopa, and carbidopa
Abstract:An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.
Inventor(s): Virkki; Matti (Masala, FI), Vahervuo; Kari (Espoo, FI), Ritala; Marja (Espoo, FI), Partanen; Marja (Espoo, FI), Niskanen; Mervi (Espoo, FI), Lintulaakso; Jarmo (Espoo, FI), Laaksonen; Marja (Masala, FI), Kervinen; Lasse (Helsinki, FI), Kallioinen; Sari (Espoo, FI)
Assignee: Orion Corporation (Espoo, FI)
Application Number:09/605,529
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,500,867
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation; Use; Process;

Drugs Protected by US Patent 6,500,867

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Orion Pharma STALEVO 100 carbidopa; entacapone; levodopa TABLET;ORAL 021485-002 Jun 11, 2003 AB RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF PARKINSON'S DISEASE ➤ Sign Up
Orion Pharma STALEVO 125 carbidopa; entacapone; levodopa TABLET;ORAL 021485-006 Aug 29, 2008 AB RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF PARKINSON'S DISEASE ➤ Sign Up
Orion Pharma STALEVO 150 carbidopa; entacapone; levodopa TABLET;ORAL 021485-003 Jun 11, 2003 AB RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF PARKINSON'S DISEASE ➤ Sign Up
Orion Pharma STALEVO 200 carbidopa; entacapone; levodopa TABLET;ORAL 021485-004 Aug 2, 2007 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF PARKINSON'S DISEASE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,500,867

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Finland991485Jun 30, 1999

Non-Orange Book US Patents Family Members for Patent 6,500,867

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,797,732 Pharmaceutical composition comprising entracapone, levodopa, and carbidopa ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Federal Trade Commission
Citi
Argus Health
Boehringer Ingelheim
US Department of Justice
Healthtrust
Cipla
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.